Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials

Nature Medicine has published an author correction to the povorcitinib hidradenitis suppurativa STOP-HS1 and STOP-HS2 phase 3 randomized, double-blind, placebo-controlled trials. The correction fixes the upper limit of baseline disease duration, discontinuation details in the Figure 1 legend, a P value superscript in Table 2, colors and label positions in Extended Data Figures 5e and 5f, and row order in Supplementary Table 6A. The HTML and PDF versions have been updated.